FDA Issues Updates Statement on Fungal Meningitis Outbreak - Additional Patient Notification Advised
Published: Oct 17, 2012
The U.S. Food and Drug Administration is informing healthcare professionals that, as a result of the ongoing investigation of New England Compounding Center (NECC), a patient with possible meningitis potentially associated with epidural injection of an additional NECC product, triamcinolone acetonide, has been identified through active surveillance and reported to FDA.
Triamcinolone acetonide is a type of steroid injectable product made by NECC. The cases of meningitis identified to date have been associated with methylprednisolone acetate, another similar steroid injectable product. In addition, two transplant patients with Aspergillus fumigatus infection who were administered NECC cardioplegic solution during surgery have been reported.
Want to read the full alert and receive alert emails?
